After few decades of knowledge supported by many one-arm, non-randomised, one-center trials. Finally the randomised trial showing that AHSCT in better in MS than DMDs. Full text here: https://www.ncbi.nlm.nih.gov/pubmed/30644983
Advertisements
-
Recent Posts
- AHSCT is a standard of care of RRMS
- Wykłady na kursie specjalizacyjnym – transplantologia
- AHSCT is better choice than DMDs in MS as a treatment of cases progressing after first line treatment – multicenter randomised trial.
- CPX-351 (Vyxeos) – new drug that improves treatment in older patients with secondary AML
- Complementary Medicine (alternative medicine) not so good for cancer patients
Ostatnio czytane
Doctors
Interesting
Patients
Productivity
Students
Social
Advertisements
That data is really impressive. If we take into account facts from other clinical trials (dr Mark Freedman’s trial) such as:
– patients ‘normalised’ their rate of brain volume loss or atrophy after myeloablative HSCT
– third of these patients, who have had lumbar punctures, have lost their OCBs.
source: (https://multiple-sclerosis-research.org/2018/12/all-i-want-for-christmas-is-a-cure/)
we might be just ‘a trial away’ from heaving a cure for MS.
One of the problems is HSCT’s impact on fertility. Since MS often strikes before one became a parent, deciding to go with HSCT is a very though decision to make. That risk alone makes me stick with DMDs.
Is there any new research on fertility after HSCT (especially male fertility)? Can we expect any progress on this issue?
Piotr, for men it is very simple – I send my patients to nOvum for Oncofertility program – and they have their sperm banked. We have succesful pregnancies in patients after AHSCT. For women – there is some of my research that was published on that topic. But for women – if you do not do AHSCT and the disease progresses – they will not have children. If you do HSCT – you will reduce the likehood of having children, but still they will be able to get pregnant and have healthy children.